Kadmon (NYSE:KDMN) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Kadmon (NYSE:KDMNGet Rating) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

KDMN opened at $9.50 on Monday. Kadmon has a twelve month low of $3.19 and a twelve month high of $9.50. The business’s fifty day moving average price is $9.50.

About Kadmon (Get Rating)

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.